Skip to content
Medications

Liraglutide: The First-Generation GLP-1

The original GLP-1 receptor agonist — daily dosing, the SCALE trials, and where it fits today.

8 min readWritten and fact-checked against the sources below

Read this first

Educational, not medical advice. Liraglutide is a prescription medicine. Compounded liraglutide is not FDA-approved.

Liraglutide was the first-generation GLP-1 — the molecule behind Victoza® (type 2 diabetes) and Saxenda® (weight management). It's an once-daily injection, which is the main difference from the once-weekly semaglutide and tirzepatide.

How does liraglutide work?

Like the others, liraglutide mimics GLP-1 to reduce appetite and improve blood-sugar control. Because it's broken down faster, it's dosed daily rather than weekly.

What did the SCALE trial show for liraglutide?

  • Modest weight loss in the SCALE trials (Saxenda®) — less than the newer agents.
  • A1c reduction in type 2 diabetes (Victoza®).
  • Cardiovascular benefit shown in the LEADER trial (diabetes formulation).
  • Similar GI side-effect profile; daily dosing is the main practical difference.

Is liraglutide still worth using?

Liraglutide is still used, but it's generally a step down in efficacy from the newer agents. It may make sense for people who can't access or tolerate the newer options, or who prefer daily dosing.

Bottom line

Liraglutide is an established, effective GLP-1 — just older and generally less potent than semaglutide and tirzepatide. It's a prescription medicine; compounded versions are not FDA-approved. This is information, not a prescription.

Want this handled for you?

LunaRx — clinician-led GLP-1 care with a plan to come off

LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.

Start the 2-minute eligibility checkIndependent site · by LunaRx · not medical advice

Sources

Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.

  1. 1.
    SCALE: A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

    Pi-Sunyer X, et al. · New England Journal of Medicine · 2015

    56-week trial in 3,731 adults without type 2 diabetes establishing liraglutide 3.0 mg for weight management.

  2. 2.
    LEADER: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

    Marso SP, et al. · New England Journal of Medicine · 2016

    Cardiovascular outcome data for liraglutide in type 2 diabetes.

Get the weekly research update

New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.

Unsubscribe anytime. Read our privacy policy.

Related in Medications